Literature DB >> 17932815

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.

Ahmad A Tarhini1, John M Kirkwood.   

Abstract

Pfizer Inc is developing tremelimumab, a fully human monoclonal IgG2 antibody against cytotoxic T-lymphocyte-associated antigen, for the potential intravenous treatment of cancer. Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17932815

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  4 in total

1.  An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies.

Authors:  D Schönfeld; G Matschiner; L Chatwell; S Trentmann; H Gille; M Hülsmeyer; N Brown; P M Kaye; S Schlehuber; A M Hohlbaum; A Skerra
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-05       Impact factor: 11.205

Review 2.  Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.

Authors:  Ana P S Silva; Priscila V Coelho; Maristella Anazetti; Patricia U Simioni
Journal:  Hum Vaccin Immunother       Date:  2016-11-10       Impact factor: 3.452

3.  The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.

Authors:  Stefania Laurent; Paola Queirolo; Silvia Boero; Sandra Salvi; Patrizia Piccioli; Simona Boccardo; Simona Minghelli; Anna Morabito; Vincenzo Fontana; Gabriella Pietra; Paolo Carrega; Nicoletta Ferrari; Francesca Tosetti; Lung-Ji Chang; Maria Cristina Mingari; Guido Ferlazzo; Alessandro Poggi; Maria Pia Pistillo
Journal:  J Transl Med       Date:  2013-05-01       Impact factor: 5.531

4.  Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes.

Authors:  Kai Mi; Fuhui Chen; Zhipeng Qian; Jing Chen; Dongxu Lv; Chunlong Zhang; Yanjun Xu; Hongguang Wang; Yuepeng Zhang; Yanan Jiang; Desi Shang
Journal:  J Cell Mol Med       Date:  2020-11-12       Impact factor: 5.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.